SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the
"Company"), a biopharmaceutical company focused on the development
of new cancer therapies, announced that Mr. Saiid Zarrabian, Chief Executive Officer of
DelMar, will be a featured presenter at the inaugural MicroCap
Rodeo Investor Conference in Austin,
Texas at the Hilton Austin on Tuesday, October 15th at 11:30 AM (CT). Mr. Zarrabian will provide an
overview of the Company's business model and growth strategy and
will be available for one-on-one meetings.
Interested investors wishing to attend and request meetings can
register at microcaprodeo.com,
https://microcaprodeo.com/signup.
A live webcast of the corporate presentation will be available
at https://www.webcaster4.com/Webcast/Page/2134/31898 or on
the Company's website at https://www.delmarpharma.com/. A replay of
the presentations will be available for 90 days.
ABOUT DELMAR PHARMACEUTICALS, INC.
Located in
San Diego, California, DelMar is
focused on the development and commercialization of new therapies
for cancer patients who have limited or no treatment options. By
focusing on understanding tumor biology and mechanisms of treatment
resistance, the Company identifies biomarkers to personalize new
therapies in indications where patients are failing, or are unable
to tolerate, standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in
U.S. clinical trials sponsored by the National Cancer Institute
(NCI). Based on DelMar's internal research programs and these prior
NCI-sponsored clinical studies, the Company is conducting clinical
trials to support the development and commercialization of VAL-083
to solve significant unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM. In addition, DelMar has
announced the allowance of a separate IND for VAL-083 as a
potential treatment for platinum-resistant ovarian cancer.
Further information on DelMar's clinical trials can be found on
clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs
For additional information, please visit
http://delmarpharma.com/; or contact DelMar Pharmaceuticals
Investor Relations: ir@delmarpharma.com / (604) 629-5989.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the reporting of the results. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the Company's Annual Report on Form 10-K for the year
ended June 30, 2019, the Company's
Quarterly Reports on Form 10-Q, and the Company's Current Reports
on Form 8-K.
CONTACTS:
Investors:
John Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com
Media:
Jules
Abraham
Director of Public
Relations
CORE
IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-at-the-inaugural-microcap-rodeo-investor-conference-on-october-15-2019-at-1130-am-central-time-300936226.html
SOURCE DelMar Pharmaceuticals, Inc.